Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jessica Fye
JPMorgan Chase & Co, Research Division

Great. Good morning, everyone. Welcome. My name is Jess Fye, large-cap biotech analyst at JPMorgan, and we’re continuing the 44th Annual Healthcare Conference this morning with Ionis. You’re going to hear a presentation from the management team, and then we’re going to go into some Q&A. So if you have any questions in the room, just raise your hands, and someone will bring you a microphone or you can submit them online, and I can read them off the iPad up here. So with that out of the way, let me pass it over to Ionis’ CEO, Brett Monia.

Brett Monia
Founder, CEO & Director

Thank you, Jess. Good morning, everybody. Thanks for joining me today for today’s presentation. As Jess said, I’m Brett Monia, CEO of Ionis, now entering my seventh year as CEO of the company, and I couldn’t be more thrilled to present to you the remarkable progress that we’ve made over the last couple of, 3 years at Ionis, but more importantly, how the momentum we’ve built over the last couple of years has set us up for far great success this year and for many years to come to drive substantial accelerating growth, the accelerating value for all Ionis stakeholders. These are my forward-looking statements.

So six years ago, Ionis, when I moved into the CEO role, set out on a new course and the evolution of the company to evolve the company from an R&D organization to a fully integrated commercial stage leading biotechnology company with one objective in doing